My Neuroendocrine Tumors has no actionable mutations, what are my options

Treatment Options for Neuroendocrine Tumors Without Actionable Mutations

I understand this can be frustrating—not having a specific genetic target identified doesn't mean you lack treatment options. In fact, according to the NCCN Guidelines for Neuroendocrine Tumors, there are several well-established approaches for patients in your situation. Let me walk you through how doctors think about this and what options typically exist.

How Doctors Approach This Situation

When a neuroendocrine tumor (NET) doesn't have actionable mutations, your oncology team shifts focus to other important factors:

• Tumor grade and differentiation (how aggressive the tumor looks under the microscope)
• Ki-67 index (a measure of how fast cells are dividing)
• SSTR status (whether your tumor expresses somatostatin receptors—a protein that certain treatments can target)
• Tumor burden and growth rate (how much disease you have and how quickly it's progressing)
• Tumor location (pancreas, lung, GI tract, etc.)

These factors often matter MORE than specific mutations in determining the best treatment path.

---

General Treatment Approaches That Exist

1. Somatostatin Analog Therapy (SSAs)

If your tumor is SSTR-positive (expresses somatostatin receptors), this is typically a first-line option:

• Octreotide LAR or Lanreotide - these are long-acting medications given by injection
• According to NCCN Guidelines, these can help control both symptoms and tumor growth
• They work by mimicking a natural hormone that slows tumor growth
• Standard doses: octreotide LAR 20-30 mg monthly or lanreotide 120 mg monthly
• Higher doses have been shown to be safe if needed

Key point: The PROMID and CLARINET trials showed these medications can slow tumor progression in advanced NETs.

---

2. Peptide Receptor Radionuclide Therapy (PRRT)

If your tumor is SSTR-positive AND you've progressed on SSAs:

• Lutetium Lu 177 dotatate is a Category 1 recommendation (highest level of evidence)
• This is a targeted radiation therapy—the medication finds and delivers radiation directly to tumor cells
• Particularly effective for mid-gut NETs with progression
• Can be used as first-line therapy if you have high Ki-67 (≥10%) and significant tumor burden

---

3. Targeted Therapy (mTOR Inhibitors)

For patients without actionable mutations, everolimus is a preferred option:

• Everolimus is Category 1 for non-functional lung NETs and well-differentiated tumors
• Works by blocking a protein (mTOR) that helps cancer cells grow
• Particularly useful if your tumor is progressing despite SSA therapy
• Cabozantinib is also Category 1 if you've already tried everolimus

---

4. Chemotherapy

For progressive disease, several chemotherapy options exist:

According to NCCN Guidelines, these can be considered:

• Temozolomide ± capecitabine (especially effective for pancreatic NETs)
• FOLFOX (fluorouracil, leucovorin, oxaliplatin)
• Cisplatin + etoposide (for intermediate/high-grade tumors)
• Carboplatin + etoposide

These are typically used when other options have been exhausted or for more aggressive tumors.

---

5. Immunotherapy

For specific situations:

• Pembrolizumab can be considered if your tumor has:

  • MSI-H (microsatellite instability-high)
  • dMMR (mismatch repair deficiency)
  • TMB-H (tumor mutational burden-high, ≥10 mutations/megabase)

• Nivolumab + ipilimumab (checkpoint inhibitors) for high-grade tumors

---

6. Observation (Watchful Waiting)

This is an important option that's often overlooked:

• For patients with stable disease and low tumor burden, observation with regular monitoring may be appropriate
• Regular imaging and biomarker testing (like chromogranin A) track disease status
• This avoids unnecessary treatment side effects if the tumor is growing slowly

---

Questions to Ask Your Oncology Team

Since your specific situation requires your doctor's evaluation, here are targeted questions that will help guide your decision:

1. "What is my tumor's grade, Ki-67 index, and SSTR status? How do these factors influence treatment recommendations?"

2. "Is my tumor SSTR-positive? If so, should I start with a somatostatin analog, and would PRRT be appropriate if I progress?"

3. "Based on my tumor location and grade, which of these options do you recommend first: observation, SSA therapy, everolimus, or chemotherapy—and why?"

4. "What biomarkers should we monitor to track my response to treatment?" (chromogranin A, NETest, imaging intervals)

5. "If my first treatment doesn't work well, what's the sequence of options we'd try next?"

6. "Are there clinical trials available for my specific tumor type and stage that I should consider?"

---

Important Context

The absence of actionable mutations doesn't mean your tumor lacks treatment targets—it just means the targets are different. According to NCCN Guidelines, many patients without specific mutations respond well to:

• SSA therapy (if SSTR-positive)
• mTOR inhibitors like everolimus
• PRRT (if SSTR-positive)
• Chemotherapy for progressive disease

Your oncologist will determine the most appropriate approach for YOUR case based on your complete clinical picture, including tumor grade, location, growth rate, and overall health status.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.